These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 289862)

  • 41. Hypertension screening and treatment with angiotensin inhibitors. Saralasin and captopril.
    Zawada ET; Stinson J; Ramirez G
    Postgrad Med; 1980 Oct; 68(4):89-92, 94-5, 98. PubMed ID: 6999479
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of biological effects of three angiotensin II antagonists in sodium depleted hypertensive patients.
    Ogihara T; Nakamaru M; Higaki J; Hata T; Kumagai A; Kumahara Y
    Med J Osaka Univ; 1983 Sep; 34(1-2):21-5. PubMed ID: 6366501
    [No Abstract]   [Full Text] [Related]  

  • 43. Historical development of saralasin.
    Pals DT; Denning GS; Keenan RE
    Kidney Int Suppl; 1979 Mar; (9):S7-10. PubMed ID: 384071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin blockade: its clinical significance.
    Streeten DH; Anderson GH; Dalakos TH
    Am J Med; 1976 May; 60(6):817-24. PubMed ID: 1020761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The renin system in essential, renovascular and adrenocortical hypertension: an overview.
    Laragh JH
    Adv Nephrol Necker Hosp; 1977; 7():157-89. PubMed ID: 96672
    [No Abstract]   [Full Text] [Related]  

  • 46. Use of angiotensin antagonists in experimental and human renovascular hypertension.
    Maxwell MH
    Adv Nephrol Necker Hosp; 1979; 8():297-319. PubMed ID: 115245
    [No Abstract]   [Full Text] [Related]  

  • 47. Role of renin-angiotensin system in experimental hypertension in rats: plasma renin and hypotensive effect of angiotensin II antagonist.
    Yamamoto J
    Jpn Circ J; 1977 Jun; 41(6):665-75. PubMed ID: 886656
    [No Abstract]   [Full Text] [Related]  

  • 48. Abnormalities of sodium and water metabolism with special reference to hypertensive diseases.
    Mizukoshi H; Miyazaki T; Araki Y
    Nihon Rinsho; 1972 Nov; 30(11):2215-22. PubMed ID: 4346764
    [No Abstract]   [Full Text] [Related]  

  • 49. Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulation.
    Brunner HR; Gavras H; Laragh JH
    Prog Cardiovasc Dis; 1974; 17(2):87-98. PubMed ID: 4369198
    [No Abstract]   [Full Text] [Related]  

  • 50. The immediate pressor response to saralasin in man: a test of angiotensin II receptor vacancy.
    Wallace JM; Case DB; Laragh JH; Keim HJ; Drayer JI; Sealey JE
    Circ Res; 1979 Jan; 44(1):38-44. PubMed ID: 214254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sodium retention versus renin-angiotensin system in experimental renal hypertension.
    Liard JF
    Can J Physiol Pharmacol; 1973 Mar; 51(3):238-41. PubMed ID: 4350180
    [No Abstract]   [Full Text] [Related]  

  • 52. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.
    Case DB; Wallace JM; Keim HJ; Sealey JE; Laragh JH
    Am J Med; 1976 May; 60(6):825-36. PubMed ID: 1020762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of sodium depletion and angiotensin II antagonism in renal hypertensive rabbits.
    Johnson JA; Stubbs DH; Stanton M; Payne C; Ichikawa S; Keitzer WF
    Am J Physiol; 1977 Oct; 233(4):H514-9. PubMed ID: 910968
    [No Abstract]   [Full Text] [Related]  

  • 54. Angiotensin blockade in renovascular hypertension: a controlled, prospective study.
    Marks LS; Maxwell MH; Gross C; Waks U; Kaufman JJ
    Br J Urol; 1977 Jun; 49(3):181-8. PubMed ID: 334316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The significance of renin and angiotensin in renovascular hypertension in man.
    Fagard R; Amery A; Billiet L; Joossens JV; Lijnen P; Reybrouck T
    Acta Clin Belg; 1979; 34(3):130-9. PubMed ID: 506622
    [No Abstract]   [Full Text] [Related]  

  • 56. Study of sar-ala8 angiotensin II (saralasin) responsiveness in hypertension of renal origin.
    Arendell R; Lawson JD; Petracek MR; Meacham PW; Hollifield JW; Dean RH
    J Surg Res; 1978 Apr; 24(4):284-7. PubMed ID: 642496
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of 1-Sar-8-Ala-angiotensin II on systemic and pulmonary haemodynamics in hypertensive patients.
    Fagard R; Amery A; Lijnen P; Reybrouck T; Joossens JV; Billiet L; Moerman E; De Schaepdryver A
    Clin Exp Pharmacol Physiol; 1978; 5(5):457-64. PubMed ID: 729204
    [No Abstract]   [Full Text] [Related]  

  • 58. The effect of angiotensin II blockade by saralasin (1-Sar-8-Ala-angiotensin II) in normal man.
    Ibsen H; Kappelgaard AM; Nielsen MD; Giese J
    Eur J Clin Pharmacol; 1978 Nov; 14(3):171-6. PubMed ID: 729612
    [No Abstract]   [Full Text] [Related]  

  • 59. Saralasin (1-sar-8-ala-angiotensin II): pharmacology and clinical use in angiotensin-dependent hypertension.
    Streeten DH; Castellian AW; Micalizzi ER; Dalakos TG; Anderson GH; Freiberg JM; Keenan RE
    Contrib Nephrol; 1976; 3():52-70. PubMed ID: 1026370
    [No Abstract]   [Full Text] [Related]  

  • 60. Changes of hemodynamics and glomerular ultrafiltration in renal hypertension of rats.
    Schwietzer G; Gertz KH
    Kidney Int; 1979 Feb; 15(2):134-43. PubMed ID: 513481
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.